CGON
Price
$18.71
Change
-$3.52 (-15.83%)
Updated
Apr 3, 04:59 PM (EDT)
Capitalization
1.7B
35 days until earnings call
NAMS
Price
$18.00
Change
-$0.21 (-1.15%)
Updated
Apr 3, 04:59 PM (EDT)
Capitalization
2B
34 days until earnings call
Ad is loading...

CGON vs NAMS

Header iconCGON vs NAMS Comparison
Open Charts CGON vs NAMSBanner chart's image
CG Oncology
Price$18.71
Change-$3.52 (-15.83%)
Volume$56.26K
Capitalization1.7B
NewAmsterdam Pharma
Price$18.00
Change-$0.21 (-1.15%)
Volume$25.25K
Capitalization2B
CGON vs NAMS Comparison Chart
Loading...
CGON
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
NAMS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
CGON vs. NAMS commentary
Apr 04, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CGON is a Hold and NAMS is a Hold.

Ad is loading...
COMPARISON
Comparison
Apr 04, 2025
Stock price -- (CGON: $22.24 vs. NAMS: $18.21)
Brand notoriety: CGON and NAMS are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CGON: 204% vs. NAMS: 141%
Market capitalization -- CGON: $1.43B vs. NAMS: $2B
CGON [@Biotechnology] is valued at $1.43B. NAMS’s [@Biotechnology] market capitalization is $2B. The market cap for tickers in the [@Biotechnology] industry ranges from $299.64B to $0. The average market capitalization across the [@Biotechnology] industry is $2.21B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CGON’s FA Score shows that 0 FA rating(s) are green whileNAMS’s FA Score has 1 green FA rating(s).

  • CGON’s FA Score: 0 green, 5 red.
  • NAMS’s FA Score: 1 green, 4 red.
According to our system of comparison, NAMS is a better buy in the long-term than CGON.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CGON’s TA Score shows that 4 TA indicator(s) are bullish while NAMS’s TA Score has 6 bullish TA indicator(s).

  • CGON’s TA Score: 4 bullish, 5 bearish.
  • NAMS’s TA Score: 6 bullish, 4 bearish.
According to our system of comparison, NAMS is a better buy in the short-term than CGON.

Price Growth

CGON (@Biotechnology) experienced а -16.20% price change this week, while NAMS (@Biotechnology) price change was -19.28% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -8.57%. For the same industry, the average monthly price growth was -10.69%, and the average quarterly price growth was -14.76%.

Reported Earning Dates

CGON is expected to report earnings on May 08, 2025.

NAMS is expected to report earnings on May 07, 2025.

Industries' Descriptions

@Biotechnology (-8.57% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
NAMS($2B) has a higher market cap than CGON($1.7B). CGON YTD gains are higher at: -22.455 vs. NAMS (-29.144). CGON has higher annual earnings (EBITDA): -95.94M vs. NAMS (-241.49M). NAMS has more cash in the bank: 834M vs. CGON (541M). CGON has less debt than NAMS: CGON (296K) vs NAMS (448K). NAMS has higher revenues than CGON: NAMS (45.6M) vs CGON (684K).
CGONNAMSCGON / NAMS
Capitalization1.7B2B85%
EBITDA-95.94M-241.49M40%
Gain YTD-22.455-29.14477%
P/E RatioN/AN/A-
Revenue684K45.6M2%
Total Cash541M834M65%
Total Debt296K448K66%
TECHNICAL ANALYSIS
Technical Analysis
CGONNAMS
RSI
ODDS (%)
Bullish Trend 2 days ago
90%
Bullish Trend 2 days ago
88%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
90%
Bullish Trend 2 days ago
55%
Momentum
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
42%
MACD
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
40%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
83%
Bearish Trend 2 days ago
54%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
83%
Bearish Trend 2 days ago
53%
Advances
ODDS (%)
Bullish Trend 23 days ago
75%
Bullish Trend 22 days ago
71%
Declines
ODDS (%)
Bearish Trend 3 days ago
88%
Bearish Trend 2 days ago
70%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
90%
Bullish Trend 2 days ago
64%
Aroon
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
71%
View a ticker or compare two or three
Ad is loading...
CGON
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
NAMS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
LBSCX32.34N/A
N/A
Columbia Dividend Income C
GSXAX34.49N/A
N/A
abrdn US Small Cap Equity A
NEXTX28.81N/A
N/A
Shelton Sustainable Equity Investor
IMOPX3.41N/A
N/A
Voya MidCap Opportunities Port S2
MSOPX28.70N/A
N/A
Morgan Stanley Inst Global Opp C

CGON and

Correlation & Price change

A.I.dvisor indicates that over the last year, CGON has been loosely correlated with SYRE. These tickers have moved in lockstep 48% of the time. This A.I.-generated data suggests there is some statistical probability that if CGON jumps, then SYRE could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CGON
1D Price
Change %
CGON100%
+0.86%
SYRE - CGON
48%
Loosely correlated
+1.27%
IDYA - CGON
46%
Loosely correlated
+10.70%
KRYS - CGON
46%
Loosely correlated
+3.68%
ACLX - CGON
44%
Loosely correlated
+10.76%
OLMA - CGON
43%
Loosely correlated
-0.30%
More

NAMS and

Correlation & Price change

A.I.dvisor indicates that over the last year, NAMS has been loosely correlated with QURE. These tickers have moved in lockstep 50% of the time. This A.I.-generated data suggests there is some statistical probability that if NAMS jumps, then QURE could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NAMS
1D Price
Change %
NAMS100%
-0.92%
QURE - NAMS
50%
Loosely correlated
+7.16%
CMRX - NAMS
50%
Loosely correlated
+0.24%
CRDF - NAMS
34%
Loosely correlated
-1.63%
GYRE - NAMS
32%
Poorly correlated
+10.61%
CGON - NAMS
29%
Poorly correlated
+0.86%
More